MTVA Stock Analysis: Buy, Sell, or Hold?
MTVA - MetaVia Inc. Common Stock
$1.48
0.06 (4.23%)
▲
5d:
+2.07%
30d:
+0.0%
90d:
+2.78%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When MTVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MTVA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: MTVA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: MTVA is currently trading at $1.48, which is considered slightly low relative to its 30-day fair value range of $1.42 to $1.75.
Technical Outlook: Technically, MTVA is showing sideways momentum. Immediate support is located at $1.38, while resistance sits at $1.64. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: MTVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.33 (+1206.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MTVA is showing sideways momentum. Immediate support is located at $1.38, while resistance sits at $1.64. The stock is showing strong short-term momentum, up 4.2% recently.
Market Sentiment: MTVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.33 (+1206.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.42 -
$1.75
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.2%)
- BULLISH: Trading 1206.3% below Wall St target ($19.33)
Trading Range Analysis
30-Day Trading Range
$1.42 -
$1.75
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.38
Resistance Level
$1.64
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.61
Wall Street Target
$19.33
(+1206.3%)
Share & Embed Analysis
Last updated: August 04, 2026 12:52 AM ET
Data refreshes hourly during market hours. Next update: 1:52 AM
Data refreshes hourly during market hours. Next update: 1:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MTVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$386 | 43 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
